55745-83-0

Usage

Uses

Used in Pharmaceutical Research:
2-Piperazin-1-yl-benzothiazole is used as a key intermediate in the synthesis of 1,8-Naphthyridone derivatives, which are being studied for their potential as inhibitors of HIV-1 replication. 2-Piperazin-1-yl-benzothiazole's unique structure allows for the development of new therapeutic agents that can target and suppress the replication of the HIV virus, offering a promising avenue for the treatment of HIV/AIDS.
In the context of HIV-1 research, 2-Piperazin-1-yl-benzothiazole is utilized for its ability to interact with specific biological targets and pathways involved in the viral life cycle. Its incorporation into 1,8-Naphthyridone derivatives enables the design of novel inhibitors that can effectively combat the virus, providing a valuable tool in the ongoing fight against HIV/AIDS.

InChI:InChI=1/C11H13N3S/c1-2-4-10-9(3-1)13-11(15-10)14-7-5-12-6-8-14/h1-4,12H,5-8H2

Upstream product

• 110-85-0 piperazine 
• 615-20-3 2-chlorobenzo[d][1,3]thiazole 
• 7144-49-2 2-methanesulfonylbenzothiazole 
• 87691-87-0 3-(1-piperazinyl)-1,2-benzisothiazole 
• 498-94-2 isonipecotic acid 
• 1028328-19-9 2,3 diaminothiophenol 
• 95-16-9 1,3-Benzothiazole 
• 2516-40-7 2-bromo-1,3-benzothiazole 
• 7542-23-6 piperazine hydrochloride 
• 142-64-3 piperazine dihydrochloride 
• 232263-41-1 ethyl 4-(benzothiazol-2-yl)-piperazin-1-carboxylate 
• 149-30-4 2-Mercaptobenzothiazole 
• 615-22-5 2-methylmercaptobenzothiazole 

Downstream Products

• 57260-43-2 1-benzothiazol-2-yl-4-[3-(4-methoxy-phenyl)-acryloyl]-piperazine 
• 1423160-52-4 2-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-5-(4-methoxyphenyl)-1,3,4-oxadiazole 
• 1423160-53-5 2-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-5-(4-nitrophenyl)-1,3,4-oxadiazole 
• 1423160-54-6 2-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-5-p-tolyl-1,3,4-oxadiazole 
• 1423160-55-7 2-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-5-(4-chlorophenyl)-1,3,4-oxadiazole 
• 1423160-56-8 2-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-5-(4-fluorophenyl)-1,3,4-oxadiazole 
• 1423160-57-9 2-((3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propyl)thio)-5-(4-bromophenyl)-1,3,4-oxadiazole 
• 1423160-58-0 2-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-5-(4-tert-butoxyphenyl)-1,3,4-oxadiazole 
• 1423160-59-1 4-(5-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-1,3,4-oxadiazol-2-yl)phenol 
• 1423160-60-4 2-(3-(4-(benzo[d]thiazol-2-yl)piperazin-1-yl)propylthio)-5-phenyl-1,3,4-oxadiazole 
• 1616492-93-3 ethyl 7-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]-1-(3-chloro-2-fluorobenzyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 
• 1616493-07-2 ethyl 7-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]-1-(2-fluorobenzyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 
• 1616493-08-3 ethyl 7-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]-1-(3-chlorobenzyl)-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 
• 1616493-09-4 ethyl 7-[4-(1,3-benzothiazol-2-yl)piperazin-1-yl]-1-benzyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylate 

Relevant academic research and scientific papers

Piperazine propanol derivative as a novel antifungal targeting 1,3-β-D-glucan synthase

1,3-β-D-Glucan synthase, which synthesizes a main component of fungal cell wall, is one of the promising targets for antifungal agents. In order to identify novel chemical classes of 1,3-β-D-glucan synthase inhibitors, we screened a chemical library monit

On the photoisomerization of the benzisothiazole portion of ziprasidone

Photostability challenge of ziprasidone in solution shows that the benzisothiazole moiety undergoes isomerization to the corresponding benzthiazole. A model compound, 3-piperazinyl-1,2-benzisothiazole, also undergoes this photoisomerization. Identification of the products has been confirmed by synthesis of the proposed molecules.

Synthesis and evaluation of new 2-piperazinylbnenzothiazoles with high 5-HT(1A) and 5-HT3 affinities

Original 2-piperazinylbenzothiazole derivatives were synthesized and studied as mixed ligands for serotoninergic 5-HT(1A) and 5-HT3 receptors. The studied compounds exhibited significant affinities for these two serotoninergic receptor subtypes. The pharmacological profile of these ligands was agonist for 5-HT(1A) receptors and antagonist for 5-HT3 receptor subsites. Compounds with such a pharmacological profile are of clinical relevance in the treatment of psychotropic diseases (eg anxiety, depression and schizophrenia). The present paper reports the chemistry and the in vitro pharmacological evaluation of these ligands.

Buchwald-Hartwig Amination of Coordinating Heterocycles Enabled by Large-but-Flexible Pd-BIAN-NHC Catalysts**

A new class of large-but-flexible Pd-BIAN-NHC catalysts (BIAN=acenaphthoimidazolylidene, NHC=N-heterocyclic carbene) has been rationally designed to enable the challenging Buchwald-Hartwig amination of coordinating heterocycles. This robust class of BIAN-NHC catalysts permits cross-coupling under practical aerobic conditions of a variety of heterocycles with aryl, alkyl, and heteroarylamines, including historically challenging oxazoles and thiazoles as well as electron-deficient heterocycles containing multiple heteroatoms with BIAN-INon (N,N′-bis(2,6-di(4-heptyl)phenyl)-7H-acenaphtho[1,2-d]imidazol-8-ylidene) as the most effective ligand. Studies on the ligand structure and electronic properties of the carbene center are reported. The study should facilitate the discovery of even more active catalyst systems based on the unique BIAN-NHC scaffold.

Copper(ii) ions supported on functionalized graphene oxide: an organometallic nanocatalyst for oxidative amination of azolesviaC-H/C-N bond activation

Graphene oxide (GO) was chemically modified withpara-aminobenzoic acid (PABA) to immobilize copper(ii) ions on its surface and used as a nanocatalyst for the oxidative C(sp2)-H bond amination reaction. A practical method to prepare Cu2+supported onpara-aminobenzoic acid grafted on GO was reported. The prepared Cu2+@GO/PABA was characterized by FT-IR, XRD, SEM, AFM, TEM, UV-Vis, and ICP techniques. The results showed that the morphology, distribution, and loading of copper ions could be well-adjusted by grafting of PABA on GO. Moreover, just 2 mol% of Cu2+@GO-PABA could catalyze the C-H activation reaction of benzoxazole and benzothiazole with secondary amines in >94% yields. Also, the catalyst showed very good recyclability and much less leaching of the Cu into the reaction solution. The high activity of Cu2+@GO-PABA can be ascribed to the good synergistic effects of Cu2+andpara-aminobenzoic acid grafted on graphene oxide.

Selective targeting of the αC and DFG-out pocket in p38 MAPK

The p38 MAPK cascade is a key signaling pathway linked to a multitude of physiological functions and of central importance in inflammatory and autoimmune diseases. Although studied extensively, little is known about how conformation-specific inhibitors alter signaling outcomes. Here, we have explored the highly dynamic back pocket of p38 MAPK with allosteric urea fragments. However, screening against known off-targets showed that these fragments maintained the selectivity issues of their parent compound BIRB-796, while combination with the hinge-binding motif of VPC-00628 greatly enhanced inhibitor selectivity. Further efforts focused therefore on the exploration of the αC-out pocket of p38 MAPK, yielding compound 137 as a highly selective type-II inhibitor. Even though 137 is structurally related to a recent p38 type-II chemical probe, SR-318, the data presented here provide valuable insights into back-pocket interactions that are not addressed in SR-318 and it provides an alternative chemical tool with good cellular activity targeting also the p38 back pocket.

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

2-Substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and preparation method and application thereof

The invention discloses 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue and a preparation method and application thereof, and particularly, relates to 2-substituted-phenyl-oxy-5-methylsulfonyl piperazine acidamide analogue with a formula (I) compound and a preparation method and application thereof, wherein substitutions in the formula (I) compound are defined as in the description. This serial compound can inhibit the activity of glycine transport protein-1 (GlyT1), is useful in treating related diseases in central nerve and psychological fields, for example, schizophrenia (including positive symptoms, negative symptoms and cognitive symptoms), senile dementia, Parkinson's disease and other related psychological diseases, is widely applicable to the drugs for preventing and treating central nerve and psychological diseases, and is expected to be developed into new-generation GlyT1 inhibitors.

Pd-Catalyzed Synthesis of Piperazine Scaffolds under Aerobic and Solvent-Free Conditions

A facile Pd-catalyzed methodology providing an efficient synthetic route to biologically relevant arylpiperazines under aerobic conditions is reported. Electron donating and sterically hindered aryl chlorides were aminated to afford yields up to 97%, with examples using piperazine as solvent, illustrating an ecofriendly, cost-effective synthesis of these privileged structures.

2-Benzazolyl-4-Piperazin-1- Ylsulfonylbenzenecarbohydroxamic acids as novel selective histone deacetylase-6 inhibitors with antiproliferative activity

We have screened our compound collection in an established cell based assay that measures the derepression of an epigenetically silenced transgene, the locus derepression assay. The screen led to the identification of 4-[4-(1-methylbenzimidazol-2-yl)piperazin-1- yl]sulfonylbenzenecarbohydroxamic acid (9b) as an active which was found to inhibit HDAC1. In initial structure activity relationships study, the 1-methylbenzimidazole ring was replaced by the isosteric heterocycles benzimidazole, benzoxazole, and benzothiazole and the position of the hydroxamic acid substituent on the phenyl ring was varied. Whereas compounds bearing a para substituted hydroxamic acid (9a-d) were active HDAC inhibitors, the meta substituted analogues (8a-d) were appreciably inactive. Compounds 9a-d selectively inhibited HDAC6 (IC50 = 0.1-1.0μM) over HDAC1 (IC50 = 0.9-6μM) and moreover, also selectively inhibited the growth of lung cancer cells vs. patient matched normal cells. The compounds induce a cell cycle arrest in the S-phase while induction of apoptosis is neglible as compared to controls. Molecular modeling studies uncovered that the MMGBSA energy for interaction of 9a-d with HDAC6 was higher than for HDAC1 providing structural rationale for the HDAC6 selectivity.